期刊文献+

47例甲状腺癌中FasL检测的病理学意义 被引量:2

Pathological significance of investigating FasL in 47 cases of thyroid adenocarcinoma
暂未订购
导出
摘要 目的:探讨甲状腺癌FasL的表达及其意义。方法:采用免疫组化S-P法检测12例正常甲状腺组织,27例甲状腺乳头状癌和20例甲状腺髓样癌中FasL的表达,并分析FasL表达与甲状腺癌发生发展的关系。结果:甲状腺乳头状癌中均可见强弱不等的FasL表达,B组中FasL呈高表达的阳性率为81.8%,A组中则为31.2%,二者间有显著差异P<0.05,在甲状腺乳头状癌中有明显间质浸润以及缺少淋巴细胞反应和肿瘤周边邻近正常组织区域癌细胞FasL表达均较强。95%的甲状腺髓样癌FasL呈高表达。结论:结果提示在甲状腺乳头状癌中FasL的高表达与肿瘤侵袭性有关,FasL表达愈强则预示其预后不良。肿瘤细胞高表达FasL可能使瘤细胞具有逃避机体免疫监视的作用。在甲状腺髓样癌中FasL的表达与甲状腺被膜浸润转移无关。 Objective:To investigate the expression of FasL and its significance in thyroid adenocarcinomas. Methods: Immunohis-tochemical staining(S- P method) was used to detect expression of FasL in formalin - fixed and paraffin - embeded tissues from 27 cases of thyroid papillary adenocarcinomas(TPA) ,20 medullary carcinomas(MC)and 12 normal thyroid tissues. The relationship between the thyroid adenocarcinomas and the positive rates of FasL expression was analyzed. Results: FasL had various degrees of expression in TPA.The positive rate of high FasL expression was 81. 8% in group B,31. 2% in group A, with a significant difference of P<0. 05. In some specimens, FasL immunoreactivity was stronger at the peripheral edge of the carcinoma, which was in close contact with adjacent normal tissues. The positive rate of strong FasL expression in MC were 95% . Gonclusion :Our results suggest that high levels of FasL expression in TPA are related to tumor aggressiveness; also thyroid carcinoma cells ascape immune surveillance by the expression of FasL; these findings suggest that the expression of FasL in TPA may contribute to further metastases in the surrounding tissues. FasL expression in MC is not associated with infiltration of the thyroid capsule or recurrence after surgery and metastases.
出处 《重庆医科大学学报》 CAS CSCD 2003年第1期69-71,共3页 Journal of Chongqing Medical University
关键词 甲状腺癌 FASL 检测 病理学 甲状腺乳头状癌 甲状腺髓样癌 Thyroid papillary adenocarcinoma Thyroid medullary carcinoma FasL Immunohistochemistry
  • 相关文献

参考文献8

  • 1[1]Griffith TS, Brunner T, Fletcher SM, et al. Fas Ligand induced apoptosis as a mechanism of immune privilege[ J ]. Science, 1995; 270 (5239): 1189 - 1192.
  • 2[2]Kagi D, Vignaux F, Ledermann B, et al. Fas and perforin pathways as major mechanisms of T cell - mediated cytotoxicity[J]. Science, 1994;265(5171) :528 - 530.
  • 3[3]O'Connell J,O'Sullivan GC, Collins, et al. The Fas coun terattack: Fas mediated T cell killing by colon cancer cells expressing Fas Ligand [ J ]. J Exp Med, 1996; 184 ( 3 ): 1075-1082.
  • 4[4]Mitsiades N, Poulaki V, Kotoula V, et al. Fas ligand ispresent in tumors of the Ewing's sarcoma family and is cleaved into a soluble form by a metalloproteinase [ J ]. Am J Pathol,1998; 153(6) :1947 - 1956.
  • 5[5]Mullauer L, Mosberger I, Chott A, et al. Fas ligand ex pression in nodal nonHodgkin' s lymphoma [ J ]. Med Pathol,1998;11(4) :369 - 375.
  • 6[6]Mitsiades N, Poulaki V, Mastorakos G, et al. Fas ligand expression in thyroid carcinoma: A potential mechanism of im mune evasion [ J ]. Endocrinol Metab, 1999; 84 ( 8 ): 2924 -2932.
  • 7[7]Tanimoto C, Hirakawa S, Kawasaki H, et al. Apoptosis in thyroid disease: a histochemical study [J]. Endocr J, 1995; 42 (2): 193 - 201.
  • 8[8]Basolo F, Pollina L, Fontanini G, et al. Apoptosis and pro liferation in thyroid carcinoma correlation with BcL - 2 and P53protein expression[J ]. Br J Cancer, 1997; 75 (4): 537 - 541.

同被引文献23

  • 1Green DR, Reed JC. Mitochondria and apoptosis [J].Science, 1998, 281(5381):1309.
  • 2Adams JM, Cory S. The bcl-2 protein family: arbiters of cell sarvivas [J]. Science, 1998, 281(5381):1322.
  • 3Gleave M, Tolcher A, Miyake H ,et al. Progression to androgen independence is delayed by adjuvant treatment with antisene bcl- 2 oligodeoxynucleotides after castration in the LNCa Prostate tumor model[J].Clin Cancer Res ,1999 ;5(10):2891-2898.
  • 4Bruckheimer EM, Brisbay S, Johnson DJ, et al. Bcl-2 accelerates multistep prostate carcinogenesis in vivo [J]. OnCogen, 2000:19 (46): 5251-8.
  • 5White E. Death-defying acts: a meeting review on apoptosis [J]. Genes Dev. 1993 ; 7(12A):2277-84.
  • 6Fas "S, Ligand F. A death factor and its receptor [J]. Adv Immunol, 1994, 57(3): 129-144.
  • 7Medreder AG. Regulation of Fas and Fas ligand expression in NK cell by cytokine and the involvement of Fas ligand in NK/LAK cell medi- ated cytotoxicity[J]. Cytokine, 1997, 23(9):394.
  • 8Takeuchi T, Sasaki Y, U eki T, et al. Modulation of growth and apoptosis response in PC23 and LNCAP prostate cancer cell lines by Fas[J]. Int J Cancer, 1996, 67(8):709-714.
  • 9Le Deist F, Emile J F, Rieux Laucat F et al. Clinical immunological and pathological consequences of Fas deficient conditions[J]. Lancet, 1996, 34(8):719.
  • 10Sasak i Y,A lamed H, Takeuchi T, et al. Immunohistochemical study of Fas, Fas ligand and interleukin-1 beta converting enzyme expression in human prostatic cancer [J]. Br J Urol, 1998, 81(6): 852.

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部